1 / 6

China Heparin Industry Development & Industry Challenges Report to 2015

Changshan Biochemical Pharmaceutical and Hefei Zhaoke were top3 enterprises in the domestic low molecular heparin calcium market, with total market share of 88.7% in 2014. GSK is the leading enterprises in this segment for a long time, but its growth has slowed down in recent 2 to 3 years. Changshan’s product achieved rapid development relying on independent pricing, which is gradually becoming the import substitution product.

jayram
Télécharger la présentation

China Heparin Industry Development & Industry Challenges Report to 2015

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Research on China Heparin Industry, 2015 Single User License: US$ 2000 No of Pages: 92 Corporate User License: US$ 3200 www.rnrmarketresearch.com WEBSITE

  2. Research on China Heparin Industry, 2015 In-depth analysis of Heparin Industry in China , 2015 Report. Currently there are 4 major products in the global low molecular heparin preparation market: SNY’s enoxaparin sodium, Pfizer’s dalteparin sodium, GSK’s nadroparin calcium and LEO’s tinzaparin sodium. Among which, enoxaparin remains the best –selling product even though its sales amount continued to decline in recent years. Though enoxaparin always dominates the international heparin preparation market, low molecular heparin calcium is more competitive in China. Low molecular heparin calcium ranked the first position in the usage among sample hospitals in 2014, and has achieved a CAGR of 23% in the past 8 years. Moreover, enoxaparin, heparin sodium and low molecular heparin sodium ranked from 2nd to 4th respectively. These 4 products accounts for 63.6% in Chinese anticoagulant market in 2014. ViewComplete Report @ http://www.rnrmarketresearch.com/research-on-china-heparin-industry-2015-market-report.html

  3. Research on China Heparin Industry, 2015 There are 7 major players in Chinese low molecular heparin calcium market, 6 of them are domestic enterprises. Enoxaparin sodium was imported from SNY in 2003 and in 2006 the generic drug produced by Jiuyuan Gene Engineering Co., Ltd came into market. Currently there are 4 domestic enterprises with volume production. The sales amount of enoxaparin in city public hospitals reached RMB 153 million in 2014. In 2014, GSK, Changshan Biochemical Pharmaceutical and Hefei Zhaoke were top3 enterprises in the domestic low molecular heparin calcium market, with total market share of 88.7% in 2014. GSK is the leading enterprises in this segment for a long time, but its growth has slowed down in recent 2 to 3 years. Changshan’s product achieved rapid development relying on independent pricing, which is gradually becoming the import substitution product. Purchase a Copy of this Report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=411478

  4. Research on China Heparin Industry, 2015 In May 2015, Qianhong Bio-Pharma received the approval letter of enoxaparin sodium API and injection from CFDA. This made Qianhong the 5th enterprises for producing enoxaparin sodium in domestic market. (Time to volume production is still uncertain). In 2014, GSK, Changshan Biochemical Pharmaceutical and Hefei Zhaoke were top3 enterprises in the domestic low molecular heparin calcium market, with total market share of 88.7% in 2014. GSK is the leading enterprises in this segment for a long time, but its growth has slowed down in recent 2 to 3 years. Changshan’s product achieved rapid development relying on independent pricing, which is gradually becoming the import substitution product. In May 2015, Qianhong Bio-Pharma received the approval letter of enoxaparin sodium API and injection from CFDA. This made Qianhong the 5th enterprises for producing enoxaparin sodium in domestic market. (Time to volume production is still uncertain). Access Report by Chisult Insight at http://www.rnrmarketresearch.com/publisher/Chisult-Insight.html

  5. Research on China Heparin Industry, 2015 Data Charts Application of Heparin PreparationsHeparin Industry ChainMarket Size of Heparin Preparation Worldwide and YoY Growth, 2006-2014Performance Comparison Between Low Molecular Weight Heparin Preparation and Unfractionated Heparin PreparationMarket Size of Global Heparin Preparations by Product, 2010-2014Regional Distribution of Heparin Preparations Worldwide, 2014Global Heparin API Demand and YoY Growth, 2007-2014Major Heparin Preparation Producers WorldwideSales of Major Heparin Preparation Brands Globally, 2010-2014Global Market Size of Heparin Preparations, 2012-2016Read more Inquire for Discount @ http://www.rnrmarketresearch.com/contacts/discount?rname=411478

  6. RnR Market ResearchRnRMarketResearch.com, An online repository of market  research reports, offers in-depth analysis of over 5000 market segments. RNR market research library has syndicated reports by leading market research  publishers across the globe. For more details contact :sales@rnrmarketresearch.Com/ +18883915441FOLLOW US Website www.rnrmarketresearch.com

More Related